Unlike traditional care models that often leave patients to navigate treatment alone, Hims & Hers delivers access to a holistic weight loss program that combines personalized dosing when clinically necessary, 24/7 care team access, and educational support across nutrition, mental health, and physical wellness
The translation of the discovery into therapies has transformed diabetes management, beginning with the approval of exenatide, the first GLP-1 receptor agonist (GLP-1RA), in 2005 by the U.S
Comparison between the effects of sitagliptin and liraglutide on blood glucose and cognitive function of patients with both type 2 diabetes mellitus and post-stroke mild cognitive impairment
doi:10.1016/S0140-6736(23)01053-X PubMed: This trial evaluated retatrutide in 281 participants with type 2 diabetes, showing up to 16.94% weight loss and significant HbA1c reductions with favorable safety profile comparable to other GLP-1 based therapies
SGLT-2, sodium-glucose cotransporter-2
Lancet 406 , 149162 (2025)